| Literature DB >> 33072162 |
Jing Guo1, Nicole Schupf1,2,3,4, Richard P Mayeux1,2,3,4, Yian Gu1,2,3,4.
Abstract
BACKGROUND: It is important to assess the temporal reproducibility of circulating cytokines for their utility in epidemiological studies. However, existing evidence is limited and inconsistent, especially for the elderly population.Entities:
Keywords: Cytokines; Elderly population; Reproducibility; Serum
Year: 2020 PMID: 33072162 PMCID: PMC7556943 DOI: 10.1186/s12979-020-00201-0
Source DB: PubMed Journal: Immun Ageing ISSN: 1742-4933 Impact factor: 6.400
Characteristics of participants across three repeated measurements
| Characteristics | The 1st measurement | The 2nd measurement | The 3rd measurement |
|---|---|---|---|
| Sample size | 65 | 65 | 65 |
| Age (years), mean (SD) | 77.89 (6.14) | 82.50 (4.85) | 84.43 (4.85) |
| 65–75, n (%) | 23 (35.38%) | 5 (7.69) | 2 (3.08) |
| 75–80, n (%) | 19 (29.23%) | 13 (20.00) | 9 (13.85) |
| ≥ 80, n (%) | 23 (35.38%) | 47 (72.31) | 54 (83.08) |
| Gender, n (%) | |||
| Male | 32 (49.23) | 32 (49.23) | 32 (49.23) |
| Female | 33 (50.77) | 33 (50.77) | 33 (50.77) |
| Race/ethnicity, n (%) | |||
| White | 22 (33.85) | 22 (33.85) | 22 (33.85) |
| Black | 21 (32.31) | 21 (32.31) | 21 (32.31) |
| Hispanic | 22 (33.85) | 22 (33.85) | 22 (33.85) |
| Education duration (years), mean (SD) | 12.26 (4.95) | 12.26 (4.95) | 12.26 (4.95) |
| BMI categories, n (%) a | |||
| Normal | 14 (26.42) | 14 (25.45) | 16 (29.09) |
| Overweight | 19 (35.85) | 20 (36.36) | 22 (40.00) |
| Obese | 20 (37.74) | 21 (38.18) | 17 (30.91) |
| Time of day of blood collection, n (%) a | |||
| Ante meridiem | 29 (58.00) | 37 (57.81) | 43 (66.15) |
| Post meridiem | 21 (42.00) | 27 (42.19) | 22 (33.85) |
| WHICAP wave, n (%) | |||
| The second wave (1999 cohort) | 36 (55.38) | 36 (55.38) | 36 (55.38) |
| The third wave (2009 cohort) | 29 (44.62) | 29 (44.62) | 29 (44.62) |
| Baseline hypertension, n (%) | |||
| No | 5 (7.69) | – | – |
| Yes | 60 (92.31) | – | – |
| Baseline diabetes, n (%) | |||
| No | 46 (70.77) | – | – |
| Yes | 19 (29.23) | – | – |
| Baseline cardiovascular diseases, n (%) | |||
| No | 28 (43.08) | – | – |
| Yes | 37 (56.92) | – | – |
SD standard deviance, n number of subjects, % proportion, BMI body mass index, WHICAP Washington Heights-Inwood Community Aging Project.
aSum of frequency of some characteristics was less than 65 at specific measurement due to missing data
Levels of serum cytokines
| Cytokines | Intra-assay CV (%) | Inter-assay CV (%) | Detectable proportions (%) a | Median (P25-P75) (pg/mL) | Range (pg/mL) |
|---|---|---|---|---|---|
| EGF | 0.91 | 7.19 | 99.49 | 226.71 (126.59, 374.77) | < 3.17 to 1657 |
| Eotaxin | 1.37 | 3.48 | 100 | 134.79 (98.66, 183) | 8.46 to 562.15 |
| FGF-2 | 1.68 | 7.56 | 88.72 | 48.23 (23.39, 105.09) | < 13.05 to 429.02 |
| Flt-3 L | 3.17 | 7.99 | 3.29 (3.29, 30.1) | < 4.65 to 1769 | |
| Fractalkine | 2.05 | 12.69 | 21.48 (18.72, 61.34) | < 26.48 to > 9834 | |
| G-CSF | 3.06 | 8.69 | 91.28 | 20.45 (11.17, 49.02) | < 3.97 to 404.65 |
| GM-CSF | 7.45 | 6.89 | 80.51 | 7.58 (3.54, 17.48) | < 3.16 to 1287 |
| GRO | 1.07 | 4.65 | 77.44 | 2216 (1264, 7288.5) | 470.26 to > 9906 |
| IFNα2 | 5.34 | 5.92 | 7.9 (3.23, 25.39) | < 4.57 to 924.48 | |
| IFNγ | 0.44 | 8.50 | 75.38 | 5.06 (2.07, 11.76) | < 2.04 to 1183 |
| IL-10 | 5.26 | 4.49 | 2.21 (2.21, 3.21) | < 3.13 to 1304 | |
| IL-12p40 | 3.47 | 6.37 | 4.79 (4.79, 11.68) | < 6.78 to 605.62 | |
| IL-12p70 | 0.99 | 2.68 | 2.02 (2.02, 3.74) | < 2.85 to 655.57 | |
| IL-13 | 3.05 | 5.86 | 3.33 (3.33, 6.25) | < 4.71 to 598.37 | |
| IL-15 | 4.94 | 6.30 | 2.04 (2.04, 4.3) | < 2.88 to 153.79 | |
| IL-17 | 2.90 | 4.36 | 70.77 | 2.57 (0.73, 7.72) | < 1.03 to 451.19 |
| IL-1α | 9.92 | 5.47 | 3.6 (3.6, 25.14) | < 5.09 to 3539 | |
| IL-1β | 5.15 | 8.15 | 1.48 (0.88, 4.86) | < 1.24 to 2581 | |
| IL-1RA | 3.02 | 8.20 | 90.26 | 15.7 (7.66, 31.01) | < 3.65 to 3857 |
| IL-2 | 3.14 | 4.48 | 1.98 (1.98, 3.62) | < 2.80 to 86.71 | |
| IL-3 | 11.71 | 12.30 | 1.97 (1.97, 1.97) | < 2.78 to 13.07 | |
| IL-4 | 8.57 | 7.22 | 83.51 | 31.18 (9.96, 79.75) | < 5.42 to 375.29 |
| IL-5 | 4.03 | 1.87 | 0.76 (0.76, 0.94) | < 1.07 to 72.28 | |
| IL-6 | 4.99 | 6.19 | 1.32 (1.32, 19.72) | < 1.86 to 7220 | |
| IL-7 | 5.37 | 4.70 | 2.64 (2.34, 7.73) | < 3.31 to 119.38 | |
| IL-8 | 2.91 | 4.22 | 97.44 | 36.4 (15.12, 245.41) | 3.84 to > 9613 |
| IL-9 | 3.91 | 5.98 | 1.99 (1.99, 1.99) | < 2.81 to 128.69 | |
| IP-10 | 2.69 | 3.44 | 100 | 222.35 (175.6, 307.84) | 49.15 to 1009 |
| MCP-1 | 3.53 | 5.93 | 100 | 590.84 (429.88, 902.12) | 118.05 to 9309 |
| MCP-3 | 0.72 | 5.50 | 61.54 | 6.17 (2.47, 34.91) | < 3.50 to 2891 |
| MDC | 9.14 | 8.11 | 100 | 1043 (758.06, 1409) | 234.05 to 6725 |
| MIP-1α | 8.53 | 5.06 | 88.21 | 19.24 (6.44, 69.77) | < 3.12 to > 5472 |
| MIP-1β | 0.65 | 6.53 | 99.49 | 48.04 (28, 89.12) | < 4.50 to 1251 |
| PDGF-AA | 2.00 | 3.91 | 99.49 | 3576 (2533.5, 4803.5) | 305.27 to > 8786 |
| PDGF-AB/BB | 6.91 | 9.83 | 9490 (8841, 9490) | 3148 to > 9490 | |
| RANTES | 8.08 | 12.69 | 96.92 | 2730 (1845.5, 3724.5) | 619.28 to > 13,438 |
| sCD40L | 1.74 | 6.59 | 84.10 | 9529 (4893.5, 13,789) | < 2.86 to > 17,067 |
| TGFα | 1.09 | 16.03 | 66.15 | 4.72 (2.18, 8.31) | < 3.09 to > 5120 |
| TNFα | 2.78 | 7.59 | 95.90 | 16.48 (9.66, 27.52) | < 2.93 to 716.76 |
| TNFβ | 4.15 | 5.78 | 2.01 (2.01, 2.01) | < 2.84 to 639.95 | |
| VEGF | 4.22 | 7.00 | 88.21 | 161.45 (71.86, 326.21) | < 20.50 to 919.48 |
CV coefficient of variation, P-P the 25th to the 75th percentiles, EGF epidermal growth factor, FGF-2 fibroblast growth factor 2, Flt-3 L fms-like tyrosine kinase 3 ligand, G-CSF granulocyte colony-stimulating factor, GM-CSF granulocyte macrophage colony-stimulating factor, GRO growth regulated oncogene, IFNα2 interferon alpha 2, IFNγ interferon gamma, IL interleukin, IL-1RA interleukin-1 receptor antagonist, IP-10 interferon gamma-induced protein 10, MCP monocyte chemotactic protein, MDC macrophage-derived chemokine, MIP macrophage inflammatory proteins, PDGF platelet-derived growth factor, RANTES regulated on activation, normal T cell expressed and secreted, TGF transforming growth factor, TNF tumor necrosis factor, VEGF vascular endothelial growth factor, sCD40L soluble cluster of differentiation 14 ligand.
aValues in bold mean that the proportions of subjects with detectable values (between LLOD and ULOD) were < 60%. A total of 18 cytokines were excluded in the further data analyses due to the low detectable rate
Fig. 1ICC (95% CI) of cytokines. The dots and horizontal bars represent the ICC and corresponding confidence intervals, respectively. ICC was estimated by the mixed-effects model adjusting for age at recruitment, gender, race/ethnicity and time spans across blood collection. The ICC levels of 0.40 ~ 0.75 and > 0.75 are corresponding to fair to good and strong reliabilities, respectively. ICC: intraclass correlation coefficient; CI: confidence interval
Fig. 2ICC (95% CI) of cytokine levels stratified by the median (4.49 years) of time interval between the 1st and 3rd measures. The dots and horizontal bars represent the ICC and corresponding confidence intervals, respectively. Results of the subjects with time spans < 4.49 years (n = 32) and ≥ 4.49 years (n = 33) were plotted in the panel (a) and (b), respectively. ICC: intraclass correlation coefficient; CI: confidence interval